Ligand Pharmaceuticals Incorporated Total Liabilities
Ligand Pharmaceuticals Incorporated total liabilities. Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has total liabilities worth $1.22 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LGND days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Ligand Pharmaceuticals Incorporated (1994–2025)
Total liabilities of Ligand Pharmaceuticals Incorporated from 1994 to 2025. This chart illustrates how Ligand Pharmaceuticals Incorporated's total liabilities have evolved over time, based on quarterly financial data. Check LGND cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Ligand Pharmaceuticals Incorporated Competitors by Total Liabilities
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanxi LuAn Environmental Energy Development Co Ltd
SHG:601699
|
China | CN¥32.74 Billion |
|
Turkiye Halk Bankasi
IS:HALKB
|
Turkey | TL4.73 Trillion |
|
Definity Financial Corp
TO:DFY
|
Canada | CA$8.90 Billion |
|
China Molybdenum Co. Ltd
F:D7N
|
Germany | €118.78 Billion |
|
COVIVIO UNS.ADR/1/4
F:F5D0
|
Germany | €12.69 Billion |
|
Adani Total Gas Limited
NSE:ATGL
|
India | Rs42.34 Billion |
|
Telekom Austria AG
VI:TKA
|
Austria | €5.10 Billion |
|
China Natl Chem Engineering Co
SHG:601117
|
China | CN¥174.47 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Ligand Pharmaceuticals Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LGND total asset value.
Liquidity & Leverage Metrics
Ligand Pharmaceuticals Incorporated Total Liabilities Ratios Explained
Ligand Pharmaceuticals Incorporated total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ligand Pharmaceuticals Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below shows the annual total liabilities of Ligand Pharmaceuticals Incorporated from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $543.42 Million | +388.10% |
| 2024-12-31 | $111.33 Million | +29.00% |
| 2023-12-31 | $86.30 Million | -47.75% |
| 2022-12-31 | $165.18 Million | -65.33% |
| 2021-12-31 | $476.43 Million | -27.01% |
| 2020-12-31 | $652.76 Million | -10.30% |
| 2019-12-31 | $727.68 Million | +3.97% |
| 2018-12-31 | $699.89 Million | +177.32% |
| 2017-12-31 | $252.37 Million | +9.38% |
| 2016-12-31 | $230.73 Million | +0.52% |
| 2015-12-31 | $229.54 Million | -1.75% |
| 2014-12-31 | $233.62 Million | +323.99% |
| 2013-12-31 | $55.10 Million | -29.15% |
| 2012-12-31 | $77.78 Million | -31.60% |
| 2011-12-31 | $113.70 Million | +37.74% |
| 2010-12-31 | $82.55 Million | -24.92% |
| 2009-12-31 | $109.95 Million | -39.52% |
| 2008-12-31 | $181.81 Million | +26.12% |
| 2007-12-31 | $144.16 Million | -51.74% |
| 2006-12-31 | $298.70 Million | -29.72% |
| 2005-12-31 | $425.04 Million | +4.23% |
| 2004-12-31 | $407.78 Million | +76.89% |
| 2003-12-31 | $230.53 Million | +17.26% |
| 2002-12-31 | $196.59 Million | +12.12% |
| 2001-12-31 | $175.35 Million | +4.04% |
| 2000-12-31 | $168.55 Million | +5.21% |
| 1999-12-31 | $160.20 Million | -4.30% |
| 1998-12-31 | $167.40 Million | +129.00% |
| 1997-12-31 | $73.10 Million | +8.14% |
| 1996-12-31 | $67.60 Million | +3.21% |
| 1995-12-31 | $65.50 Million | +221.08% |
| 1994-12-31 | $20.40 Million | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more